CONCERT PHARMACEUTICALS INC's ticker is CNCE and the CUSIP is 206022105. A total of 102 filers reported holding CONCERT PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $2,440 | -99.9% | 417,858 | +2.3% | 0.00% | – |
| Q3 2022 | $2,736,000 | +166.1% | 408,489 | +67.2% | 0.00% | – |
| Q2 2022 | $1,028,000 | +20.5% | 244,373 | -3.5% | 0.00% | – |
| Q1 2022 | $853,000 | +5.3% | 253,184 | -1.5% | 0.00% | – |
| Q4 2021 | $810,000 | -27.9% | 257,143 | -25.2% | 0.00% | – |
| Q3 2021 | $1,123,000 | -17.0% | 343,700 | +7.2% | 0.00% | – |
| Q2 2021 | $1,353,000 | -49.6% | 320,622 | -40.5% | 0.00% | – |
| Q1 2021 | $2,687,000 | -44.3% | 538,521 | +41.2% | 0.00% | -100.0% |
| Q4 2020 | $4,820,000 | +34.4% | 381,367 | +4.4% | 0.00% | 0.0% |
| Q3 2020 | $3,587,000 | +1.0% | 365,317 | +2.4% | 0.00% | 0.0% |
| Q2 2020 | $3,551,000 | +19.1% | 356,913 | +5.8% | 0.00% | 0.0% |
| Q1 2020 | $2,981,000 | -38.7% | 337,280 | -36.0% | 0.00% | 0.0% |
| Q4 2019 | $4,860,000 | +236.3% | 527,000 | +114.4% | 0.00% | – |
| Q3 2019 | $1,445,000 | -50.9% | 245,764 | +0.2% | 0.00% | -100.0% |
| Q2 2019 | $2,944,000 | +7.4% | 245,367 | +8.0% | 0.00% | 0.0% |
| Q1 2019 | $2,740,000 | -47.3% | 227,088 | -45.3% | 0.00% | 0.0% |
| Q4 2018 | $5,204,000 | +54.7% | 414,794 | +82.9% | 0.00% | 0.0% |
| Q3 2018 | $3,365,000 | -1.4% | 226,764 | +11.8% | 0.00% | 0.0% |
| Q2 2018 | $3,412,000 | -18.9% | 202,748 | +10.3% | 0.00% | 0.0% |
| Q1 2018 | $4,208,000 | -2.9% | 183,795 | +9.7% | 0.00% | 0.0% |
| Q4 2017 | $4,334,000 | +125.0% | 167,584 | +28.3% | 0.00% | 0.0% |
| Q3 2017 | $1,926,000 | +7.7% | 130,602 | +1.9% | 0.00% | 0.0% |
| Q2 2017 | $1,788,000 | -26.6% | 128,182 | -10.2% | 0.00% | 0.0% |
| Q1 2017 | $2,435,000 | +66.8% | 142,740 | +0.6% | 0.00% | 0.0% |
| Q4 2016 | $1,460,000 | -2.5% | 141,902 | -4.3% | 0.00% | 0.0% |
| Q3 2016 | $1,498,000 | -5.0% | 148,228 | +5.5% | 0.00% | 0.0% |
| Q2 2016 | $1,577,000 | -17.8% | 140,469 | +0.0% | 0.00% | 0.0% |
| Q1 2016 | $1,918,000 | -22.1% | 140,421 | +8.2% | 0.00% | 0.0% |
| Q4 2015 | $2,461,000 | +2.9% | 129,779 | +1.9% | 0.00% | 0.0% |
| Q3 2015 | $2,391,000 | +70.2% | 127,386 | +34.9% | 0.00% | 0.0% |
| Q2 2015 | $1,405,000 | +11.6% | 94,395 | +13.5% | 0.00% | 0.0% |
| Q1 2015 | $1,259,000 | +206.3% | 83,148 | +169.4% | 0.00% | – |
| Q4 2014 | $411,000 | +24.9% | 30,861 | +17.9% | 0.00% | – |
| Q3 2014 | $329,000 | +55.9% | 26,167 | +24.9% | 0.00% | – |
| Q2 2014 | $211,000 | -35.1% | 20,942 | -13.6% | 0.00% | – |
| Q1 2014 | $325,000 | – | 24,230 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 2,610 | $620,000,000 | 6.47% |
| Parkman Healthcare Partners LLC | 1,124,072 | $4,732,000 | 1.74% |
| Kynam Capital Management, LP | 1,000,000 | $4,210,000 | 1.08% |
| EAM Investors, LLC | 850,647 | $3,581,000 | 0.87% |
| BVF INC/IL | 3,629,000 | $15,278,000 | 0.74% |
| EAM Global Investors LLC | 388,730 | $1,637,000 | 0.40% |
| RA Capital Management | 3,307,203 | $13,923,000 | 0.37% |
| Nantahala Capital Management | 1,659,840 | $6,988,000 | 0.35% |
| AWM Investment Company, Inc. | 504,661 | $2,125,000 | 0.34% |
| INGALLS & SNYDER LLC | 1,411,153 | $5,941,000 | 0.31% |